Assembly Biosciences (FRA:V7B) Total Assets : €110.29 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Assembly Biosciences Total Assets?

Assembly Biosciences's Total Assets for the quarter that ended in Mar. 2024 was €110.29 Mil.

During the past 12 months, Assembly Biosciences's average Total Assets Growth Rate was -31.60% per year. During the past 3 years, the average Total Assets Growth Rate was -53.80% per year. During the past 5 years, the average Total Assets Growth Rate was -37.00% per year. During the past 10 years, the average Total Assets Growth Rate was 16.60% per year.

During the past 13 years, Assembly Biosciences's highest 3-Year average Total Assets Growth Rate was 895.40%. The lowest was -56.40%. And the median was 5.40%.

Total Assets is connected with ROA %. Assembly Biosciences's annualized ROA % for the quarter that ended in Mar. 2024 was -28.34%. Total Assets is also linked to Revenue through Asset Turnover. Assembly Biosciences's Asset Turnover for the quarter that ended in Mar. 2024 was 0.05.

Assembly Biosciences Total Assets Historical Data

The historical data trend for Assembly Biosciences's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assembly Biosciences Total Assets Chart

Assembly Biosciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Assets

Get a 7-Day Free Trial

305.92

232.84

169.09

96.09

125.47

Assembly Biosciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Assets	Get a 7-Day Free Trial															77.63	61.45	48.38	125.47	110.29

Assembly Biosciences Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Assembly Biosciences's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Assets	=	Total Equity (A: Dec. 2023 )	+	Total Liabilities (A: Dec. 2023 )
	=	37.686	+	87.781
	=	125.47

Assembly Biosciences's Total Assets for the quarter that ended in Mar. 2024 is calculated as

Total Assets	=	Total Equity (Q: Mar. 2024 )	+	Total Liabilities (Q: Mar. 2024 )
	=	29.993	+	80.299
	=	110.29

Assembly Biosciences (FRA:V7B) Total Assets Explanation

Total Assets is connected with ROA %.

Assembly Biosciences's annualized ROA % for the quarter that ended in Mar. 2024 is

ROA %	=	Net Income (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
	=	-33.404	/	( (125.467	+	110.292)	/ 2 )
	=	-33.404	/	117.8795
	=	-28.34 %

Note: The Net Income data used here is four times the quarterly (Mar. 2024) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Assembly Biosciences's Asset Turnover for the quarter that ended in Mar. 2024 is

	Asset Turnover
=	Revenue (Q: Mar. 2024 )	/	( (Total Assets (Q: Dec. 2023 )	+	Total Assets (Q: Mar. 2024 ))	/ count )
=	5.322	/	( (125.467	+	110.292)	/ 2 )
=	5.322	/	117.8795
=	0.05

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Assembly Biosciences Total Assets Related Terms

Thank you for viewing the detailed overview of Assembly Biosciences's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Assembly Biosciences (FRA:V7B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Assembly Biosciences Inc (FRA:V7B) » Definitions » Total Assets

Comparable Companies

Traded in Other Exchanges

ASMB:USA

Address

331 Oyster Point Boulevard, Fourth Floor, South San Francisco, CA, USA, 94080

Website

https://www.assemblybio.com

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, that are designed to restore health to a dysbiotic microbiome. The firm's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Its program targets high-recurrence genital herpes associated with herpes simplex virus type 2 (HSV-2) infection and research programs focused on the discovery of novel antivirals to treat devastating viral diseases, including hepatitis delta virus (HDV) and transplant-related herpesviruses.

Assembly Biosciences (FRA:V7B) Headlines

No Headlines